Showing 6881-6890 of 8590 results for "".
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Arkansas Gets SUNucatedhttps://practicaldermatology.com/news/arkansas-gets-sunucated/2459875/Arkansas has joined 18 other states in adopting legislation to allow children to possess and apply sunscreen at school. Governor Asa Hutchinson signed into law HB 1167, which was co-sponsored by Representative Lee Johnson, MD, and carried through the Senate by Senator David Wallace.
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- FDA Clears Sculptura Radiation Oncology System from Sensus Healthcarehttps://practicaldermatology.com/news/fda-clears-sculptura-radiation-oncology-system-from-sensus-healthcare/2459884/The FDA has granted market clearance for the Sculptura radiation oncology system from Sensus Healthcare, Inc. With a single treatment during surgery, Sculptura can provide cancer patients and physicians a single radiation treatment at the
- Hoth Therapeutics Names Dr. Adam Friedman to Scientific Advisory Boardhttps://practicaldermatology.com/news/hoth-therapeutics-names-dr-adam-friedman-to-scientific-advisory-board/2459887/Hoth Therapeutics, Inc. has named Adam Friedman, MD to the Company's Scientific Advisory Board. Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Scientific Adviso
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&